IP Library Granted Patent US 11,795,241
Granted Patent B2
US 11,795,241 · App. 17/103,328 · Granted Oct 24, 2023

Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same

Inventors: Vincent D. Antle (Olathe, KS); Charles Alan Watson (Louisburg, KS); David W. Miles (Kansas City, MO)
Assignee: CyDex Pharmaceuticals, Inc.
C08B37/0006A61K47/40A61K47/6951B01D15/325C08B37/0003C08B37/0012C08L5/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,795,241
App. No.
17/103,328
Granted
Oct 24, 2023
Kind
B2
Abstract

The present invention relates to compositions comprising fractionated alkylated cyclodextrin compositions having a single degree of substitution, and processes for preparing and using the same.

Claims (13)

1. A process for preparing a fractionated alkylated cyclodextrin composition comprising an alkylated cyclodextrin, the process comprising:

(a) preparing a solution comprising an alkylated cyclodextrin composition;

(b) passing the solution through a reversed phase high performance liquid chromatography system having a stationary phase and a mobile phase; and

(c) collecting a fractionated alkylated cyclodextrin composition comprising 85% by weight or more alkylated cyclodextrin having a selected single degree of substitution relative to all alkylated cyclodextrin in the composition; wherein the single degree of substitution is 4, 5, 6, 7, 8, 9, 10, 11, or 12;

wherein the alkylated cyclodextrin is a sulfoalkyl ether cyclodextrin of Formula (II):

wherein p is 4, 5, or 6, and R 1 is independently selected at each occurrence from —OH or —O—(C 2 -C 6 alkylene)-SO 3 − -T, wherein T is independently selected at each occurrence from pharmaceutically acceptable cations, provided that at least one R 1 is —OH and at least one R 1 is O—(C 2 -C 6 alkylene)-SO 3 − -T.

2. The process of claim 1 , wherein the chromatographic separation system is high performance liquid chromatography.

3. The process of claim 1 , wherein the stationary phase is a silica gel column.

4. The process of claim 1 , wherein the mobile phase comprises acetonitrile.

5. The process of claim 4 , wherein the mobile phase further comprises an ammonium acetate buffer.

6. The process of claim 1 , wherein R 1 is independently selected at each occurrence from —OH or —O—(C 4 alkylene)-SO 3 − -T, and -T is Na + at each occurrence.

7. The process of claim 1 , further comprising combining the fractionated alkylated cyclodextrin composition with one or more excipients.

8. The process of claim 1 , further comprising combining the fractionated alkylated cyclodextrin composition with an active agent.

Assignments (2)
SECURITY INTEREST Recorded Oct 18, 2023
From: CYDEX PHARMACEUTICALS, INC.; LIGAND PHARMACEUTICALS INCORPORATED; METABASIS THERAPEUTICS, INC.; PFENEX INC.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065271/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: ANTLE, VINCENT D.; WATSON, CHARLES ALAN; MILES, DAVID W.
To: CYDEX PHARMACEUTICALS, INC.
Reel/Frame 061322/0654 →
Continuity (3)
Continuation 15505428
Provisional Application 62040568 · Aug 22, 2014
Related Publication 20210147582A1 · May 20, 2021
Cited By (1)
US 12,674,005